Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

458

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

August 31, 2027

Conditions
Orthopaedic PolytraumaChronic Opioid Use
Interventions
DRUG

Ketorolac Injection

Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin Reference ID: 3281582 3 synthetase inhibition. The biological activity of ketorolac tromethamine is associated with the S-form. Ketorolac tromethamine possesses no sedative or anxiolytic properties.

OTHER

Normal Saline

0.9% Sodium Chloride Injection, USP is sterile and nonpyrogenic. It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration. Each 100 mL of 0.9% Sodium Chloride Injection, USP contains 900 mg sodium chloride in water for injection. Electrolytes per 1000 mL: sodium (Na+) 154 mEq; chloride (Cl-) 154 mEq. The osmolarity is 308 mOsmol/L (calc.).

Trial Locations (2)

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Massachusetts General Hospital

OTHER